… a correlation between pharmacokinetics and pharmacogenomics of another EGFR-… EGFR
mutation-positive advanced NSCLC, the pharmacokinetics of gefitinib and pharmacogenomics …

… pharmacogenomics, pharmacokinetics, and pharmacodynamics among patients with cancer.
… of these EGFR-activating mutations occur in exons 18 to 21 and predict response to EGFR …

… wild-type patients while having less of an impact on the tumor response in EGFR mutation-…
population pharmacokinetics and pharmacogenomics of erlotinib and its pharmacokinetic and …

… of this report is that egfr mutations were never found along with Kras mutations, and were …
placebo 177 samples were analyzed for egfr mutations, and a mutation incidence of 22% was …

… pharmacokinetics (PKs) of olmutinib in three racial subjects. We also evaluate safety/tolerability
and a population PK and pharmacogenomic … Pharmacogenomic analysis indicated that …

… for low-dose afatinib (30 mg/day) use in elderly patients with NSCLC with EGFR mutation to
assess quality-of-life (QOL) and pharmacokinetic (PK)/pharmacogenomic (PGx) parameters. …

… a major effect on drug pharmacokinetics and pharmacodynamics. EGFR, encoding the direct
… An intronic microsatellite polymorphism has been associated with EGFR expression, with …

… cancer (NSCLC) harboring EGFR mutation. The orally administered … pharmacokinetics.
The aim of this study was to evaluate the association of pharmacokinetics or pharmacogenomics …

… /pharmacogenomic label for these EGFR antibodies indicating that tumors with KRAS
mutations … A population pharmacokinetic–pharmacogenetic model of tacrolimus was presented …

… growth factor receptor (EGFR) gene. Drug resistance caused by EGFR mutations and genetic
… and transporters impedes effective treatment of EGFR mutant and resistant lung cancer. …